Avinger (AVGR) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Avinger (NASDAQ:AVGR) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Zacks Investment Research currently has $0.25 price objective on the medical device company’s stock.

According to Zacks, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California. “

Shares of Avinger (NASDAQ:AVGR) opened at $0.20 on Wednesday. Avinger has a 12-month low of $0.17 and a 12-month high of $3.66.

In related news, Chairman John B. Ph D. Md Simpson sold 454,584 shares of Avinger stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $0.27, for a total transaction of $122,737.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John B. Ph D. Md Simpson sold 1,074,130 shares of Avinger stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $0.25, for a total value of $268,532.50. The disclosure for this sale can be found here. 17.00% of the stock is currently owned by company insiders.

A hedge fund recently bought a new stake in Avinger stock. AWM Investment Company Inc. bought a new position in shares of Avinger Inc (NASDAQ:AVGR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,150,000 shares of the medical device company’s stock, valued at approximately $516,000. AWM Investment Company Inc. owned 4.81% of Avinger as of its most recent SEC filing. Institutional investors own 3.79% of the company’s stock.

WARNING: “Avinger (AVGR) Upgraded at Zacks Investment Research” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2018/01/06/avinger-avgr-upgraded-at-zacks-investment-research.html.

About Avinger

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.

Get a free copy of the Zacks research report on Avinger (AVGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Avinger? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Avinger and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit